Comparative Pharmacology
Head-to-head clinical analysis: SULSTER versus SULTEN 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULSTER versus SULTEN 10.
SULSTER vs SULTEN-10
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulster is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folate synthesis and thus bacterial DNA replication.
Selectively inhibits type 5 phosphodiesterase (PDE5), enhancing cyclic guanosine monophosphate (cGMP) accumulation, leading to smooth muscle relaxation and vasodilation in the corpus cavernosum.
2.5 mg orally twice daily.
1 to 2 tablets (10-20 mg) orally once daily, preferably in the morning.
None Documented
None Documented
Terminal half-life 3.5-4.5 hours in normal renal function; prolonged to 10-15 hours with creatinine clearance <30 mL/min.
Terminal elimination half-life is 12-15 hours; clinically, this supports once-daily dosing with steady state achieved in 3-5 days.
Primarily renal (60-70% unchanged), with 20-30% as glucuronide conjugate; biliary/fecal <10%.
Primarily renal excretion of unchanged drug (approx. 70-80%) with the remainder as inactive metabolites (10-15% fecal, 5-10% biliary).
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic